Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Vitrafy Life Sciences Ltd. ( (AU:VFY) ).
Vitrafy Life Sciences Limited reported a 15.1% increase in revenue from ordinary activities to $8,868 for the half-year ended 31 December 2025, while significantly narrowing its loss after tax to $7.1 million, a 72.3% improvement from the prior corresponding period’s $25.7 million loss. Despite the reduced deficit, the company’s net tangible assets per ordinary security declined to 33.91 cents from 45.16 cents, and no dividends were paid or declared, underscoring its continued emphasis on capital preservation and reinvestment as it works toward financial sustainability; the half-year financial statements were reviewed by auditors, reinforcing transparency for shareholders during this transition period.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited operates in the life sciences sector, focusing on technologies and services that support biomedical and healthcare applications. The company is listed on the ASX and reports under Australian Accounting Standards, which are equivalent to IFRS, indicating a focus on compliance with international financial reporting norms for its investor base.
Average Trading Volume: 34,975
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$108.5M
Find detailed analytics on VFY stock on TipRanks’ Stock Analysis page.